EXACT SCIENCES WKN: 590273 ISIN: US30063P1057 Kürzel: EXAS Forum: Aktien Thema: Hauptdiskussion

🎈

Wird wieder auf 60 euro steigen

💥💥💥💥💥💥

Crasht noch viel tiefer die kommenden Wochen

🥵🥵🥵

💣💣💣💣💣

💣🥵

Sieht schlecht aus fallen vermutlich noch 72 % mM

Und am 12.01. haben die noch einen Auftritt bei der J.P. Morgan Healthcare Conference. Kann sein, dass sich bei dem Kurs in dieser Woche was tut. Wenn der Hahn kräht auf dem Mist, ändert sich der Kurs, oder er bleibt, wie er ist.

Die vorläufigen Quartsalzahlen liegen wohl etwas besser als erwartet: https://www.prnewswire.com/news-releases/exact-sciences-announces-preliminary-fourth-quarter-2021-results-301456792.html

Auch von heute: Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients https://www.prnewswire.com/news-releases/exact-sciences-and-oncxerna-announce-licensing-agreement-to-help-predict-immunotherapy-response-for-more-patients-301456787.html

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients https://www.prnewswire.com/news-releases/exact-sciences-acquires-preventiongenetics-to-accelerate-availability-of-hereditary-cancer-testing-for-more-patients-301456755.html

Das Ding geht wegen Mainz Biomed runter. Das wird ne Wachablösung

Kauft lieber den deutschen konkurrenten mainz biomed gerade mk von 110mio

Exact Sciences announces third quarter 2021 results MADISON, Wis., Nov. 2, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. (PRNewsfoto/Exact Sciences Corporation) "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat cancer through earlier detection," said Kevin Conroy, chairman and CEO. "Our powerful commercial engine will help us achieve our mission by getting more people tested with Cologuard®, Oncotype DX®, and our future tests." Third quarter 2021 financial results For the three-month period ended September 30, 2021, as compared to the same period of 2020 (where applicable): Total revenue was $456.4 million, an increase of 12 percent Screening revenue was $280.4 million, an increase of 31 percent Precision Oncology revenue was $145.4 million, an increase of 59 percent COVID-19 testing revenue was $30.6 million, a decrease of 70 percent Gross margin including amortization of acquired intangible assets was 70%, and non-GAAP gross margin excluding amortization of acquired intangible assets was 75% Intangible asset impairment of $20.2 million was related to a supply agreement asset recorded as part of the combination with Genomic Health Net loss was $166.9 million, or $0.97 per share, compared to a net loss of $202.5 million, or $1.35 per share EBITDA was $(119.9) million, and adjusted EBITDA was $(16.3) million Cash, cash equivalents, and marketable securities were $1.22 billion at the end of the quarter Screening includes laboratory service revenue from Cologuard tests and revenue from Biomatrica products. Precision Oncology includes laboratory service revenue from global Oncotype products and laboratory service revenue from Ashion. 2021 outlook The company anticipates revenue of $1,722-$1,737 million during 2021, including Screening revenue of $1,050-$1,055 million, Precision Oncology revenue of $547-$552 million, and COVID-19 testing revenue of $125-$130 million. Updated revenue guidance has been narrowed toward the high end of our previously expected range of $1,705-$1,745 million, which included Screening revenue of $1,100-$1,125 million, Precision Oncology revenue of $530-$540 million, and COVID-19 testing revenue of $75-$80 million. Screening revenue expectations are lower due to the rapid rise in Delta variant cases starting in late July, causing in-person sales calls to significantly decrease in August and September

Exact Sciences EPS misses by $0.27, beats on revenue; Screening revenue guidance lowered Jul. 28, 2021 4:11 PMExact Sciences Corporation (EXAS)By: Mamta Mayani, SA News Editor Exact Sciences (NASDAQ:EXAS): Q2 GAAP EPS of -$1.03 misses by $0.27. Revenue of $434.82M (+61.7% Y/Y) beats by $14.37M. Non-GAAP gross margin of 74%. Shares -7.1%. 2021 outlook: The company anticipates revenue of $1,705-$1,745 million from $1,690-$1,735 million, including Screening revenue of $1,100-$1,125 million from $1,125-$1,150 million, Precision Oncology revenue of $530-$540 million from $515-$525 million, and COVID-19 testing revenue of $75-$80 million from $50-$60 million.